FDA approves Keytruda in third-line gastric cancer for patients with PD-L1 expression ≥1%: http://www.mrknewsroom.com/news-release/prescription-medicine-news/fda-approves-mercks-keytruda-pembrolizumab-previously-treate This is an accelerated approval based on ORR. The PDUFA date was today.